The National Academies of Sciences, Engineering, and Medicine Board on Population Health and Public Health Practice will host a workshop Oct. 17-18 in Washington, D.C., on health system interventions to prevent firearm injury and death. The workshop will feature evidence and best practices and examine opportunities to improve efficacy by working with communities. Participants will include Jay Bhatt, D.O., AHA senior vice president and chief medical officer; David Grossman, M.D., and Gregory Simon, M.D., senior investigators for the Kaiser Permanente Washington Health Research Institute in Seattle; Bechara Choucair, M.D., chief community officer for Kaiser Permanente National Community Health; Elizabeth McGlynn, executive director of the Kaiser Permanente Center for Effectiveness and Safety Research; Lucas Neff, M.D., assistant professor of pediatric surgery at Wake Forest University Baptist Medical Center in Winston-Salem, N.C.; and Megan Bair Merritt, M.D., executive director of the Center for the Urban Child and Healthy Family; and Thea James, M.D., director of the Violence Intervention Advocacy Program at Boston Medical Center. For details and to register, click here.

Related News Articles

Blog
As hospitals and health systems look for sustainable and scalable solutions to help address rising behavioral health needs across the country, digital tools…
Headline
The Centers for Medicare & Medicaid Services Dec. 15 published the Measures Under Consideration List for 2025. These are measures that CMS is considering…
Blog
The holiday season is often depicted as a time of joy and celebration, but for health care professionals it can also be a busy and emotionally demanding time…
Headline
The Centers for Medicare & Medicaid Services Dec. 11 announced the launch of the Make America Healthy Again: Enhancing Lifestyle and Evaluating Value-based…
Headline
The Advisory Committee on Immunization Practices Dec. 5 recommended individual-based decision-making for parents deciding whether to give the hepatitis B…
Headline
Nirsevimab was found to be 80% effective at preventing respiratory syncytial virus-associated intensive care unit admissions during the 2024-2025 RSV season,…